Identification |
Name: | 1,3,5-Triazine-2,4-diamine,6-(2,5-dichlorophenyl)-, (2Z)-2-butenedioate (1:1) |
Synonyms: | 1,3,5-Triazine-2,4-diamine,6-(2,5-dichlorophenyl)-, (Z)-2-butenedioate (1:1);2,4-Diamino-6-(2,5-dichlorophenyl)-s-triazine maleate;Gaslon;Gaslon N;MN 1695; |
CAS: | 84504-69-8 |
Molecular Formula: | C9H7Cl2N5.C4H4O4 |
Molecular Weight: | 372.17 |
InChI: | InChI=1/C9H7Cl2N5.C4H4O4/c10-4-1-2-6(11)5(3-4)7-14-8(12)16-9(13)15-7;5-3(6)1-2-4(7)8/h1-3H,(H4,12,13,14,15,16);1-2H,(H,5,6)(H,7,8)/b;2-1- |
Molecular Structure: |
|
Properties |
Specification: |
?Adverse reactions: constipation, diarrhea, nausea, vomiting, skin rash
|
Biological Activity: | Phosphodiesterase 4 (PDE4) inhibitor that displays gastroprotective properties. Prevents gastric mucosal injury induced by monochloramine and ischemia-reperfusion. Activates gap-junctional intercellular communication improving gastric mucosal barrier function. Inhibits superoxide production in human neutrophils and inhibits in vitro and in vivo angiogenesis. |
Storage Temperature: | Desiccate at RT |
Usage: | An anti-ulcer drug. |
Safety Data |
|
|